91 percent response rate for venetoclax against newly diagnosed AML in older adults

Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. Of the three patients who did not respond to treatment, two discontinued the study before the first week due to personal reasons unrelated to treatment or side-effects.

Based on these results, on November 21, the U.S. Food and Drug Administration (USFDA) granted accelerated approval for venetoclax to treat patients who are aged 75 years and older or are ineligible for intensive chemotherapy due to coexisting medical conditions. Updated clinical trial results and scientific findings will be presented December 1-4 at the 60th annual American Society of Hematology (ASH) meeting in San Diego, CA.

Traditionally, the diagnosis of AML in this population has carried an extremely poor prognosis, with median overall survival of less than a year. Already, patients on the current trial have reached a median follow-up time of 580 days. Because so many patients remain on the trial with controlled disease, it is impossible to predict the average expected duration of benefit from this new combination treatment, implying a remarkably long duration of remission.

"To date, treatment options for older patients with AML have been limited. We see this new regimen as a paradigm shift in the way we will treat this disease in this population, moving forward," says Daniel A. Pollyea, MD, MS, investigator at CU Cancer Center, clinical director of Leukemia Services at the CU School of Medicine, and the study's first author.

Azacitidine is a low-dose chemotherapy drug that has long been used in the treatment of AML, with minimal success. Venetoclax is a targeted inhibitor of the Bcl-2 protein, which earned FDA approval in 2016 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). The current regimen includes a course of azacitidine, followed by the ongoing use of venetoclax.

"Two patients on this study have been off all therapy for nearly three years, and others who remain on therapy seem to be on the same trajectory, suggesting this regimen may be curative in some settings," Pollyea says.

The trial is closely related to the preclinical work of Craig Jordan, PhD, investigator at University of Colorado Cancer Center, division chief of the Division of Hematology and the Nancy Carroll Allen Professor of Hematology at the University of Colorado School of Medicine. Basic science describing the underlying mechanism of drug action is published concurrently in the journal Cancer Cell. First author of the Cancer Cell paper Courtney Jones, PhD, and others working in the Jordan lab showed that leukemia stem cells depend on amino acid metabolism to supply themselves with energy. As part of its action against Bcl-2, venetoclax blocks cells' uptake of amino acids, and thus blocks the mechanism these cells use to generate energy, killing these cells.

"Leukemia stem cells in newly diagnosed AML patients absolutely depend on amino acid metabolism, but that's not the case for healthy cells. By taking away the ability of leukemia stem cells to metabolize amino acids, we can target these cells without affecting surrounding, healthy tissues," Jordan says.

One factor limiting treatment options in this population is the severity of side-effects associated with current therapies. Newly-diagnosed AML is most often treated with intensive chemotherapy. Unfortunately, while chemotherapy is largely effective against the bulk of leukemia cells, leukemia stem cells are uniquely equipped to resist chemotherapy, and so often survive treatment, leading to relapse. Using azacitidine alone in this population shows 28 percent response rate with response duration of 10 months. At that point, treatment often includes bone marrow transplant - eradicating a patient's cancerous blood system and repopulating a new one using blood stem cells from cord blood or from a matched donor. However, bone marrow transplant can be poorly tolerated in older and/or more frail patients.

"Many of these patients, you just can't treat in that way," Pollyea says. "They would be too likely to die from the treatment, itself - it does more harm than good."

Combining venetoclax with azacitidine was associated with no more side effects than the use of azacitidine alone.

Patients whose cancers held IDH mutations were more likely to experience long-lasting response; patients with RAS mutations often experienced shorter remissions. Initial findings suggest that treatment of AML patients who have relapsed following standard therapy is a more difficult challenge, requiring more than just venetoclax and azacitidine to achieve substantially improved outcomes.

In addition to AML and CLL, venetoclax is in clinical trials to treat cancers including acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), T cell lymphoma, non-Hodgkin lymphoma, myelodysplastic syndrome, and more (full list at clinicaltrials.gov).

The Jordan lab continues to collaborate closely with CU Cancer Center clinicians including Daniel Pollyea to further optimize strategies targeting cancer stem cells in leukemia and other cancers.

Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT.
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Nat Med. 2018 Nov 12. doi: 10.1038/s41591-018-0233-1.

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...